[HTML][HTML] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

P Manley, J Mestan, S Cowan-Jacob, A Ray… - British journal of …, 2006 - nature.com
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute
lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the …

[引用][C] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E WEISBERG - Br J Cancer, 2006 - cir.nii.ac.jp
AMN107 (nilotinib) : a novel and selective inhibitor of BCR-ABL | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …

[PDF][PDF] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan, S Cowan-Jacob… - British Journal of …, 2006 - Citeseer
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph þ)
acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib …

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

E Weisberg, P Manley, J Mestan… - British Journal of …, 2006 - search.ebscohost.com
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute
lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the …

[引用][C] AMNI07 (nilotinib): a novel and selective inhibitor of BCR-ABL

E WEISBERG, P MANLEY, I MESTAN… - British journal of …, 2006 - pascal-francis.inist.fr
AMNI07 (nilotinib) : a novel and selective inhibitor of BCR-ABL CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

E Weisberg, P Manley, J Mestan… - British Journal of …, 2006 - europepmc.org
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute
lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the …

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan… - British journal of …, 2006 - pubmed.ncbi.nlm.nih.gov
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute
lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the …

[PDF][PDF] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan… - British Journal of …, 2006 - academia.edu
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph þ)
acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib …

[PDF][PDF] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan… - British Journal of …, 2006 - researchgate.net
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph þ)
acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib …

[HTML][HTML] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

E Weisberg, P Manley, J Mestan… - British Journal of …, 2006 - ncbi.nlm.nih.gov
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute
lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. Imatinib inhibits the …